Cross 'foruming' a bit, but wouldn't Prana like to throw the money into PBT2 trials that these US bios can pour into their drugs. I suppose that any Australian biotech with a promising drug is in the same position.
No wonder it is such a slow, usually fruitless process in this country. Drugs that make it out of Aus must be very, very good or very lucky, or most probably a combination of the two. Let's hope Neuren with Trofinetide and it's follow ups will be one of those. (Also PBT2, as although I no longer hold, I will always have a soft spot for it - there is such a huge burgeoning need.)
Success in Phase 1 Alzheimer's trial adds $40 bn, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$15.21 |
Change
-0.180(1.17%) |
Mkt cap ! $1.884B | |||
| Open | High | Low | Value | Volume |
| $15.45 | $15.45 | $15.10 | $1.679M | 110.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 252 | $15.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.22 | 483 | 5 |
View Market Depth
| Last trade - 10.50am 21/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |